MedTrace Logo

Safety and Tolerability of Lu AF95245 in Healthy Young Men

NCT04199585 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-05-12

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and tolerability of Lu AF95245 and what the body does to Lu AF95245 after swallowing single doses of the drug

Conditions

  • Healthy

Interventions

DRUG

Lu AF95245

solution, single dose, orally

DRUG

Lu AF95245 14C radiolabelled spiked dosage

solution, single dose, orally

DRUG

Placebo

solution, single dose, orally

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-10
Primary Completion
2020-02-16
Completion
2020-02-19

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04199585 on ClinicalTrials.gov